2 Mar 2018 15:01
BUZZ-Verona Pharma: Soars on positive data from mid-stage study
** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
VRP.L Share News (VRP)
VRP Share
Price
VRP Share
News
VRP Share
Chat
VRP Share
Trades
VRP
Live RNS
VRP Share
Charts
VRP Broker
Ratings
VRP Directors
Deals
VRP Financial
Diary
VRP
Fundamentals
VRP Short
Positions
VRP
Media
VRP.L Information
- There is currently no data for VRP
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Verona Pharma In Talks With Licensees For RPL554 Cough Project
Mon, 28th Jun 2010 07:33
LONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has signed a letter of intent, or LOI, to look at the safety, the duration of action with respect to bronchidilation, and the extent of anti-inflammatory action of RPL554 at higher doses in two asthmatic patient trials -Second LOI signed to test the bronchodilator effects and safety of the drug in patients with established chronic obstructive pulmonary disease, or COPD. -Carrying out experimental trials designed to facilitate the administration of RPL554 in inhaler devices commonly used by asthmatics and COPD patients Cough -Regulatory documents for the proposed clinical trial of VRP700 in cough patients submitted to the ethics committee at the University of Florence and approval to proceed with the trial is expected within the next few months -It is anticipated that the trial will be completed by the end of the year - dependant on patient recruitment and the effectiveness of VRP700's anti-cough actions -Shares closed Friday at 7.38 pence valuing the company at GBP17.61 million. -By Ian Walker, Dow Jones Newswires; 44-20-7842-9296; ian.walker@dowjones.com (END) Dow Jones Newswires June 28, 2010 02:33 ET (06:33 GMT)
More News
26 Sep 2016 09:39
Verona Pharma appoints sector veteran Morgan as CFO
(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c
Read more13 Sep 2016 12:04
Verona Pharma makes progress on new respiratory drug
(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr
Read more20 Jun 2016 15:02
20 Jun 2016 12:50
Verona Pharma secures funding for drug trial
(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new
Read more3 Jun 2016 12:52
Verona Pharma's shares fall as higher R&D costs widen FY loss
(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its
Read more15 Mar 2016 10:35
Verona Pharma excites with asthma trial results
(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu
Read more21 Jan 2016 13:31